drug_type
RELEVANT_DRUG
intervention_type
antibody–drug conjugate
drug_description
HER2-directed antibody–drug conjugate composed of trastuzumab linked to the microtubule inhibitor DM1; after HER2 binding and internalization, DM1 is released to disrupt microtubules in HER2-positive cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ado-Trastuzumab Emtansine
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-directed antibody-drug conjugate in which trastuzumab binds HER2 on tumor cells and is internalized; intracellular processing releases the maytansinoid payload DM1, which inhibits microtubule assembly leading to mitotic arrest and apoptosis. The trastuzumab component also blocks HER2 signaling and can mediate ADCC.
drug_name
Ado-trastuzumab emtansine (T-DM1)
nct_id_drug_ref
NCT06068985